What is Deepcure?
Deepcure operates at the intersection of artificial intelligence and life sciences, focusing on the acceleration of drug development cycles. The company's core value proposition lies in its ability to synthesize complex biological data through machine learning, which is then validated by its sophisticated, automated laboratory systems. This dual-pronged approach allows for a more precise identification of therapeutic candidates, significantly reducing the time and capital expenditure typically associated with traditional drug discovery pipelines. As the biotech industry shifts toward data-centric methodologies, Deepcure's infrastructure serves as a critical enabler for rapid, scalable pharmaceutical research.
How much funding has Deepcure raised?
Deepcure has raised a total of $104M across 2 funding rounds:
Series A
$40M
Series A
$64M
Series A (2021): $40M with participation from The Morningside Group, TLV Partners, Benon Group, and Sapir Venture Partners
Series A (2024): $64M led by The Morningside Group, Benon Group, Sapir Venture Partners, and IAG Capital Partners
Key Investors in Deepcure
The Morningside Group
Founded in 1986 by the Chan family, this firm provides private equity and venture capital with a focus on deep industry knowledge and social responsibility.
Sapir Venture Partners
A venture firm dedicated to empowering entrepreneurs through strategic resources and support to foster innovation across emerging business sectors.
IAG Capital Partners
A venture capital firm specializing in leading investment rounds from seed to Series C, with a focus on scaling innovative companies globally.
What's next for Deepcure?
With the successful closure of this latest financing round, Deepcure is well-positioned to scale its operational capacity and expand its research initiatives. The strategic allocation of these funds will likely prioritize the enhancement of its AI algorithms and the further automation of its laboratory workflows to maintain a competitive edge in the drug discovery market. As the company transitions into its next phase of growth, stakeholders will be monitoring its ability to translate computational insights into tangible clinical assets, potentially setting new benchmarks for efficiency in the global biotech landscape.
See full Deepcure company page
